NXGL — NEXGEL, Inc.

NEXGEL Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics:

• Revenue: $2.65 million for Q1 2026, a slight decline from $2.81 million in Q1 2025.
• Cash Position: Cash and restricted cash as of March 31, 2026, was approximately $2.1 million, down to $1.8 million as of the call date.
• Funding: Raised $13.8 million, including $8.8 million in cash and a $5 million convertible note to fund the BioNX acquisition and working capital.
• SG&A Increase: Higher selling, general, and administrative expenses due to costs related to the BioNX acquisition and a settled legal case.

2. Strategic Updates and Business Highlights:

• Acquisition of BioNX: Closed in mid-April 2026, expected to significantly enhance NEXGEL's capabilities in regenerative medicine.
• Product Portfolio: BioNX includes six established regenerative biomaterial products with existing reimbursement pathways, already approved in about 500 U.S. hospitals.
• Sales Leadership: Appointment of Dave Hazard as Vice President of Sales for BioNX Surgical to drive growth.
• New CFO: Ian Blackman appointed to lead integration and scale operations.
• Product Development Pipeline: Three 510(k) devices in development, with a total investment of $4.6 million, targeted for commercialization in 2026, 2027, and 2028.

3. Forward Guidance and Outlook:

• Revenue Growth Expectation: Anticipated pro forma revenue to triple to approximately $35 million post-acquisition, with immediate profitability expected.
• Sales Recovery: Early signs of recovery in Silly George sales noted for Q2 2026, with expectations for modest growth in existing product lines.
• Operating Expenses: Projected monthly operating overhead of approximately $500,000 post-acquisition.

4. Bad News, Challenges, or Points of Concern:

• Flat Revenue Performance: Year-over-year revenue stagnation attributed to lower sales from Silly George and a poor performance in Q4 2025.
• Competitive Pressures: Increased competition impacting sales, particularly in consumer products.
• iRhythm Relationship: Sales from iRhythm have not met initial expectations, raising concerns about future revenue from this partnership.
• Short Selling Pressure: A significant number of shares sold short (350,000) may negatively impact stock performance.

5. Notable Q&A Insights:

• Sales Force Engagement: The sales force for BioNX is just beginning to ramp up post-acquisition, with contracts being finalized and training completed.
• Conservative Revenue Projections: Management is taking a cautious approach to growth estimates, particularly for non-BioNX segments, due to prior volatility.
• Integration Communication: Investors expressed a desire for more frequent updates on integration and revenue developments, particularly before the next earnings call in August.

Overall, NEXGEL is positioned for potential growth through its recent acquisition and strategic partnerships, despite facing challenges in revenue performance and competitive pressures.